Newsfeeds - Spark Newswire

5 minute read

FDA
News

BridgeBio Pharma Presents Phase 1 Data In Healthy Volunteers, Advancing Development Of BBP-671 For Pantothenate Kinase-associated Neurodegeneration And Organic Acidemias

Today, 7:02 AM

BridgeBio Pharma Presents Positive Phase 1 Data in Healthy Volunteers, Advancing Development of BBP-671 for Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Organic Acidemias - BBP-671 detected in healthy

BBIO

1 minute read

BridgeBio Partnered Protein Replacement Therapy Shows Promising Action In Painful Skin Blistering Disorder

By Vandana Singh

Today, 7:02 AM

BridgeBio Pharma Inc (NASDAQ:BBIO) and affiliate company Phoenix Tissue Repair announced data from the Phase 2 trial of PTR-01 in recessive…

BBIO

1 minute read

FDA
News

Bridgebio Pharma Says On May 12, Amended Loan And Security Agreement, Dated As Of November 17, 2021; Bridgebio Pharma Inc – Under Amendment, Parties Agreed To, Among Other Things Permit Sale Of A Certain Priority Review Voucher Issued By U.S. FDA

By Benzinga Newsdesk

Today, 7:02 AM

-SEC Filing

BBIO

3 minute read

The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio’s PRV; RMAT Designation For PolarityTE’s Product

By Vandana Singh

Today, 7:02 AM

Here's a roundup of top developments in the biotech space over the last 24 hours:

BBIO

5 minute read

The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More

By Vandana Singh

Today, 7:02 AM

Here's a roundup of top developments in the biotech space over the last 24 hours:

ACOR

57 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 7:02 AM

On Friday, 1043 companies hit new 52-week lows.

AAOI

1 minute read

BridgeBio Shares Plunge After it Details Out-Licensing Plans For ‘Restructuring Initiative’

By Vandana Singh

Today, 7:02 AM

BridgeBio Pharma Inc (NASDAQ:BBIO) estimates between $23 million to $25 million in restructuring-related costs, including write-offs of long-lived assets, severance and…

BBIO

1 minute read

BridgeBio Pharma Q1 EPS $1.35 Up From $(1.18) YoY

By Bill Haddad

Today, 7:02 AM

BridgeBio Pharma (NASDAQ:BBIO) reported quarterly earnings of $1.35 per share. This is a 214.41 percent increase over losses of $(1.18) per share from the same period last year.

BBIO